Sagient ResearchProductsAbout UsContact Us

    SAMPLE TARGET PROFILE
(Data Shown as of 05/13/10)

GLP-1 Receptor  
10-Year Revenue Outlook: U.S.  Worldwide
 
Topic Specialty Practice Thought Leader Location Date
Obesity Endocrinology New York, NY, USA 12/19/2007
Obesity Endocrinology Geneva, Switzerland 12/19/2007
Obesity Endocrinology Baton Rouge, LA, USA 12/17/2007
Obesity Endocrinology Cincinnati, OH, USA 12/05/2007
Drug Lead Company Indication  (sort) Phase   (sort) Est. Approval Date Likelihood of Approval Clinical Trial
Analysis
(Last Event)		 Peak Potential U.S. Revenue (M)
AC2592 Amylin Pharmaceuticals, Inc. (AMLN) Congestive Heart Failure (CHF) Suspended N/A 0%
(Same As Avg.) 		View Analysis
(06/29/07) 		N/A
AVE0010 Prolonged Release sanofi aventis (SNY) Diabetes Mellitus, Type II Suspended N/A 0%
(Same As Avg.) 		View Analysis
(03/04/09) 		N/A
Bydureon Amylin Pharmaceuticals, Inc. (AMLN) Diabetes Mellitus, Type II NDA 10/10 95%
(14% Above Avg.) 		View Analysis
(05/06/10)TLO 		$ 1,431.5
Byetta Amylin Pharmaceuticals, Inc. (AMLN) Diabetes Mellitus, Type II Approved 04/05 100%
(Same As Avg.) 		View Analysis
(02/26/10) 		$ 567.1
Byetta Amylin Pharmaceuticals, Inc. (AMLN) Obesity Suspended N/A 0%
(Same As Avg.) 		View Analysis
(03/27/09)TLO 		N/A
DAC:GLP-1 ConjuChem Biotechnologies, Inc. (CJB:CN) Diabetes Mellitus, Type II Suspended N/A 0%
(Same As Avg.) 		View Analysis
(09/30/05) 		N/A
Exenatide transdermal patch Amylin Pharmaceuticals, Inc. (AMLN) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(04/19/10) 		N/A
Intranasal exenatide Amylin Pharmaceuticals, Inc. (AMLN) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(01/27/10) 		N/A
ITCA 650 Intarcia Therapeutics, Inc. Diabetes Mellitus, Type II II N/A 30%
(Same As Avg.) 		View Analysis
(11/06/09) 		N/A
Lixisenatide sanofi aventis (SNY) Diabetes Mellitus, Type II III 04/12 70%
(3% Above Avg.) 		View Analysis
(04/15/10) 		$ 257.8
LY2189265 Eli Lilly & Company (LLY) Diabetes Mellitus, Type II III 01/14 69%
(2% Above Avg.) 		View Analysis
(02/24/10) 		$ 826.9
LY2428757 Eli Lilly & Company (LLY) Diabetes Mellitus, Type II II 10/14 30%
(Same As Avg.) 		View Analysis
(12/08/08) 		N/A
MAR701 Marcadia Biotech, Inc. Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(02/17/10) 		N/A
MKC-253 MannKind Corporation (MNKD) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(04/30/10) 		N/A
NN9068 Novo Nordisk A/S (NVO) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(04/27/10) 		N/A
NN9924 Novo Nordisk A/S (NVO) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(01/13/10) 		N/A
NN9925 Novo Nordisk A/S (NVO) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(04/27/10) 		N/A
Oral GLP-1 Emisphere Technologies, Inc. (EMIS) Diabetes Mellitus, Type II I N/A 20%
(Same As Avg.) 		View Analysis
(09/08/09) 		N/A
ORMD 0901 Oramed Pharmaceuticals Inc. (ORMP.OB) Diabetes Mellitus, Type II Development N/A 0%
(Same As Avg.) 		View Analysis
(09/09/09) 		N/A
PC-DAC:Exendin-4 ConjuChem Biotechnologies, Inc. (CJB:CN) Diabetes Mellitus, Type II II 04/14 25%
(5% Below Avg.) 		View Analysis
(06/08/09) 		$ 275.6
PF-04603629 Pfizer, Inc. (PFE) Diabetes Mellitus, Type II Suspended N/A 0%
(Same As Avg.) 		View Analysis
(11/03/08) 		N/A
Semaglutide Novo Nordisk A/S (NVO) Diabetes Mellitus, Type II II N/A 30%
(Same As Avg.) 		View Analysis
(04/30/09) 		N/A
Syncria GlaxoSmithKline plc (GSK) Diabetes Mellitus, Type II III 10/13 70%
(3% Above Avg.) 		View Analysis
(04/28/10) 		$ 818.0
Taspoglutide Roche Holding AG (ROG:VX) Diabetes Mellitus, Type II III 04/12 72%
(5% Above Avg.) 		View Analysis
(04/29/10) 		$ 1,421.9
TKS1225 Pfizer, Inc. (PFE) Obesity I N/A 20%
(Same As Avg.) 		View Analysis
(10/15/09) 		N/A
TT-223+LY24287 combination Eli Lilly & Company (LLY) Diabetes Mellitus, Type II II N/A 31%
(1% Above Avg.) 		View Analysis
(01/25/10) 		N/A
Victoza Novo Nordisk A/S (NVO) Diabetes Mellitus, Type II Approved 01/10 100%
(Same As Avg.) 		View Analysis
(05/06/10) 		$ 444.3
Victoza Novo Nordisk A/S (NVO) Obesity III N/A 70%
(3% Above Avg.) 		View Analysis
(02/02/10)TLO 		N/A
 
Description: Receptor for Glucagon-Like Peptide 1 (GLP-1), which is secreted from the L-cells of the gastrointestinal tract. GLP-1 has potent effects on glucose-dependent insulin secretion, insulin gene expression, and pancreatic islet cell formation. GLP-1 augments insulin secretion; decelerates gastric emptying; promotes satiety; suppresses glucagon secretion from pancreatic alpha-cells; facilitates insulin sensitivity in peripheral tissues; upregulates expression of pancreatic beta-cell genes GLUT2, glucokinase, insulin, and PDX-1; and promotes pancreatic beta-cell integrity. Recombinant versions of the peptide have pharmacologic properties that may make them suitable for energy-related metabolic disorders as well as disorders affecting a variety of organ systems.
 
 Questions? Email Subscriber Support BioMedTracker Research Standards      Privacy Policy      Important Legal Disclosure 

Copyright © 2010 Sagient Research Systems, Inc.  All rights reserved.